Vadastuximab is a humanized monoclonal antibody that selectively targets CD33, a cell surface protein predominantly expressed on myeloid cells and acute myeloid leukemia (AML) cells. This antibody is instrumental in the development of antibody-drug conjugates (ADCs) designed for targeted therapeutic applications. Research indicates that Vadastuximab can enhance the efficacy of cancer treatments by delivering cytotoxic agents directly to CD33-expressing tumors, thereby promoting precise tumor eradication while minimizing off-target effects.
Vadastuximab is a humanized monoclonal antibody that selectively targets CD33, a cell surface protein predominantly expressed on myeloid cells and acute myeloid leukemia (AML) cells. This antibody is instrumental in the development of antibody-drug conjugates (ADCs) designed for targeted therapeutic applications. Research indicates that Vadastuximab can enhance the efficacy of cancer treatments by delivering cytotoxic agents directly to CD33-expressing tumors, thereby promoting precise tumor eradication while minimizing off-target effects.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
